|
|
|
|
| LEADER |
01652nmm a2200385 u 4500 |
| 001 |
EB001902372 |
| 003 |
EBX01000000000000001065281 |
| 005 |
20240125000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
201006 ||| eng |
| 100 |
1 |
|
|a Parmar, Mahesh K. B.
|
| 245 |
0 |
0 |
|a Remdesivir COVID-19 clinical trial
|h Elektronische Ressource
|c Mahesh Parmar
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2020, 2020
|
| 300 |
|
|
|a 1 streaming audio file (12 min.))
|
| 505 |
0 |
|
|a Contents: Overview of Remdesivir -- Overview of the clinical trial -- Current outcomes -- Next steps for the clinical trial -- Published preliminary report: Beigel J. H, et al. New England Journal of Medicine 2020. doi:10.1056/NEJMoa2007764
|
| 653 |
|
|
|a Communicable Diseases, Emerging / drug therapy
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a severe acute respiratory syndrome coronavirus 2
|
| 653 |
|
|
|a Pneumonia, Viral / drug therapy
|
| 653 |
|
|
|a Clinical trials
|
| 653 |
|
|
|a remdesivir
|
| 653 |
|
|
|a Ribonucleotides
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a Antiviral agents / Development
|
| 653 |
|
|
|a COVID-19 (Disease) / Research
|
| 653 |
|
|
|a Coronavirus Infections / drug therapy
|
| 653 |
|
|
|a Antiviral Agents / administration & dosage
|
| 653 |
|
|
|a Coronavirus infections / Chemotherapy
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Research and clinical interviews
|
| 500 |
|
|
|a Audio interview. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/4317
|x Verlag
|z Streaming video file
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1060
|3 Series
|
| 082 |
0 |
|
|a 570
|